Opinion|Videos|January 21, 2025
Exploring 1L and 2L CDK4/6 Inhibitors + Endocrine Therapies
Panelists discuss how first- and second-line treatment options for HR+ advanced/metastatic breast cancer, particularly the use of CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy, are influenced by clinical factors such as bone metastasis, visceral crisis, and molecular phenotype, while also reviewing the latest clinical trial data, real-world outcomes, and comparative efficacy of ribociclib, abemaciclib, and palbociclib.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What are the available first- or second-line treatment options for HR+ advanced/metastatic breast cancer? (CDK4/6i +/- ET, etc.)
- What is the rationale for using CDK4/6i and ET in the front line?
- What are the main considerations when selecting frontline therapy? (bone metastases, visceral crisis, menopause status, recurrence score, nodal status, molecular phenotype, etc)
- Primary results from the Phase II RIGHT Choice trial
- SABCS PS2-06: Lu et al., RIGHT Choice trial subanalysis by intrinsic subtype & gene & signature expression.
- Real-world treatment outcomes (CDK4/6 inhibitors + endocrine therapy)
- OS analysis of first-line CDK4/6 inhibitors in real-world cohort
- What are the CDK4/6i options? Please briefly mention the main clinical trials and recent data:
- Ribociclib - MONALEESA-2, MONALEESA-7, MONALEESA-3
- ctDNA associated with PFS and OS in MONALEESA-3 (ML-3).
- Abemaciclib - MONARCH-3
- Final OS Analysis of Monarch 2
- Palbociclib - PALOMA-2, PARSIFAL
- Nationwide real-world practice pattern and clinical data of palbociclib
- SABCS 2024 LB1-03: Loibl et al, Primary results of the randomised phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy - PADMA study.
- Lerociclib: LEONARDA-1
- LEONARDA-2: Lerociclib plus letrozole
- How do the data for the 3 CDK4/6i compare?
Newsletter
Stay up to date on the most recent and practice-changing oncology data
SubscribeAdvertisement
Related to this article
Komal Jhaveri, MD, FACP, discusses the design of the SERENA-6 trial and larger questions for the breast cancer field that remain after seeing its results.
The oral PARG inhibitor ETX-19477 earned fast track status for BRCA-mutated, HR-positive, HER2-negative unresectable or metastatic breast cancer.
T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Advertisement
Advertisement
Trending on OncLive
1
ESMO Guidelines Express Update Recommends Daraxonrasib for RAS G12–Mutated Metastatic PDAC
2
mRNA Vaccines May Help Increase Long-Term Disease Control in PDAC
3
FDA Grants Fast Track Designation to PLN-101095 Plus Pembrolizumab in Solid Tumors
4
Harold P. Freeman, MD, Pioneer of Patient Navigation and Cancer Disparities Research, Dies at 93
5